Download PDF
CC BY-NC-ND 4.0 · Thromb Haemost 2022; 122(07): 1115-1129
DOI: 10.1055/a-1788-5322
Cellular Haemostasis and Platelets

Cucurbitacins Elicit Anti-Platelet Activity via Perturbation of the Cytoskeleton and Integrin Function

Neline Kriek
1   Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, United Kingdom
,
Sophie H. Nock
2   Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, United Kingdom
,
Tanya Sage
1   Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, United Kingdom
,
Badrija Khalifa
2   Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, United Kingdom
,
Alexander P. Bye
1   Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, United Kingdom
,
Joanne L. Mitchell
1   Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, United Kingdom
,
Steven Thomson
2   Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, United Kingdom
,
Mark G. McLaughlin
3   Department of Chemistry, Lancaster University, Lancaster, United Kingdom
,
Sarah Jones
2   Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, United Kingdom
,
Jonathan M. Gibbins
1   Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, United Kingdom
,
Amanda J. Unsworth 
1   Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, United Kingdom
2   Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, United Kingdom
› Author Affiliations Funding This work was supported by a British Heart Foundation Project Grant PG/2019/34798 (to A.J.U.) and British Heart Foundation programme grants RG/15/2/31224 and RG/20/7/34866 (to J.M.G.), and research funds from the Centre for Bioscience at Manchester Metropolitan University and a Manchester Metropolitan University Internal Research Accelerator Grant: 343846 (to A.J.U.).
› Further Information
   Permissions and Reprints

Abstract

Cucurbitacins are dietary compounds that have been shown to elicit a range of anti-tumour, anti-inflammatory and anti-atherosclerotic activities. Originally identified as signal transducer and activator of transcription, STAT, inhibitors, a variety of mechanisms of action have since been described, including dysregulation of the actin cytoskeleton and disruption of integrin function. Integrin outside-in signalling and cytoskeletal rearrangements are critical for the propagation of stable thrombus formation and clot retraction following platelet adhesion at the site of vessel damage. The effects of cucurbitacins on platelet function and thrombus formation are unknown. We report for the first time anti-platelet and anti-thrombotic effects of cucurbitacins B, E and I in human platelets. Treatment of platelets with cucurbitacins resulted in attenuation of platelet aggregation, secretion and fibrinogen binding following stimulation by platelet agonists. Cucurbitacins were also found to potently inhibit other integrin- and cytoskeleton-mediated events, including adhesion, spreading and clot retraction. Further investigation of cytoskeletal dynamics found treatment with cucurbitacins altered cofilin phosphorylation, enhanced activation and increased F actin polymerisation and microtubule assembly. Disruption to cytoskeletal dynamics has been previously shown to impair integrin activation, platelet spreading and clot retraction. Anti-platelet properties of cucurbitacins were found to extend to a disruption of stable thrombus formation, with an increase in thrombi instability and de-aggregation under flow. Our research identifies novel, anti-platelet and anti-thrombotic actions of cucurbitacins that appear to be linked to dysregulation of cytoskeletal dynamics and integrin function.

Keywords

thrombosis - platelet - cytoskeleton - cucurbitacins - signalling

Author Contributions

Contribution: N.K., S.N., T.S., B.K., A.P.B., J.L.M., S.T., performed experiments and analysed results. M.G.M., S.J. and J.M.G. designed the research and wrote the paper. A.J.U. designed the research, performed experiments, analysed results and wrote the paper.


Supplementary Material



Publication History

Received: 18 May 2021

Accepted: 06 November 2021

Accepted Manuscript online:
04 March 2022

Article published online:
30 July 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Kaushik U, Aeri V, Mir SR. Cucurbitacins - an insight into medicinal leads from nature. Pharmacogn Rev 2015; 9 (17) 12-18
    CrossrefPubMedGoogle Scholar
  • 2 Stainer AR, Sasikumar P, Bye AP. et al. The metabolites of the dietary flavonoid quercetin possess potent antithrombotic activity, and interact with aspirin to enhance antiplatelet effects. TH Open 2019; 3 (03) e244-e258
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Vaiyapuri S, Ali MS, Moraes LA. et al. Tangeretin regulates platelet function through inhibition of phosphoinositide 3-kinase and cyclic nucleotide signaling. Arterioscler Thromb Vasc Biol 2013; 33 (12) 2740-2749
    CrossrefPubMedGoogle Scholar
  • 4 Vaiyapuri S, Roweth H, Ali MS. et al. Pharmacological actions of nobiletin in the modulation of platelet function. Br J Pharmacol 2015; 172 (16) 4133-4145
    CrossrefPubMedGoogle Scholar
  • 5 Ed Nignpense B, Chinkwo KA, Blanchard CL, Santhakumar AB. Polyphenols: modulators of platelet function and platelet microparticle generation?. Int J Mol Sci 2019; 21 (01) E146
    CrossrefPubMedGoogle Scholar
  • 6 Kaneider NC, Mosheimer B, Reinisch N, Patsch JR, Wiedermann CJ. Inhibition of thrombin-induced signaling by resveratrol and quercetin: effects on adenosine nucleotide metabolism in endothelial cells and platelet-neutrophil interactions. Thromb Res 2004; 114 (03) 185-194
    CrossrefPubMedGoogle Scholar
  • 7 Chen X, Bao J, Guo J. et al. Biological activities and potential molecular targets of cucurbitacins: a focus on cancer. Anticancer Drugs 2012; 23 (08) 777-787
    CrossrefPubMedGoogle Scholar
  • 8 Alghasham AA. Cucurbitacins - a promising target for cancer therapy. Int J Health Sci (Qassim) 2013; 7 (01) 77-89
    PubMedGoogle Scholar
  • 9 Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003; 63 (06) 1270-1279
    PubMedGoogle Scholar
  • 10 Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, Sebti SM. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 2005; 24 (20) 3236-3245
    CrossrefPubMedGoogle Scholar
  • 11 Nakashima S, Matsuda H, Kurume A. et al. Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells. Bioorg Med Chem Lett 2010; 20 (09) 2994-2997
    CrossrefPubMedGoogle Scholar
  • 12 Zhang YT, Xu LH, Lu Q. et al. VASP activation via the Gα13/RhoA/PKA pathway mediates cucurbitacin-B-induced actin aggregation and cofilin-actin rod formation. PLoS One 2014; 9 (04) e93547
    CrossrefPubMedGoogle Scholar
  • 13 Kong Y, Chen J, Zhou Z, Xia H, Qiu MH, Chen C. Cucurbitacin E induces cell cycle G2/M phase arrest and apoptosis in triple negative breast cancer. PLoS One 2014; 9 (07) e103760
    CrossrefPubMedGoogle Scholar
  • 14 Jayaprakasam B, Seeram NP, Nair MG. Anticancer and antiinflammatory activities of cucurbitacins from Cucurbita andreana. Cancer Lett 2003; 189 (01) 11-16
    CrossrefPubMedGoogle Scholar
  • 15 McFarland BC, Gray GK, Nozell SE, Hong SW, Benveniste EN. Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells. Mol Cancer Res 2013; 11 (05) 494-505
    CrossrefPubMedGoogle Scholar
  • 16 Wang X, Tanaka M, Peixoto HS, Wink M. Cucurbitacins: elucidation of their interactions with the cytoskeleton. PeerJ 2017; 5: e3357
    CrossrefPubMedGoogle Scholar
  • 17 Touihri-Barakati I, Kallech-Ziri O, Ayadi W. et al. Cucurbitacin B purified from Ecballium elaterium (L.) A. Rich from Tunisia inhibits α5β1 integrin-mediated adhesion, migration, proliferation of human glioblastoma cell line and angiogenesis. Eur J Pharmacol 2017; 797: 153-161
    CrossrefPubMedGoogle Scholar
  • 18 Gupta P, Srivastava SK. Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression. Oncotarget 2014; 5 (07) 1812-1828
    CrossrefPubMedGoogle Scholar
  • 19 Gong H, Shen B, Flevaris P. et al. G protein subunit Galpha13 binds to integrin alphaIIbbeta3 and mediates integrin “outside-in” signaling. Science 2010; 327 (5963): 340-343
    CrossrefPubMedGoogle Scholar
  • 20 Durrant TN, van den Bosch MT, Hers I. Integrin αIIbβ3 outside-in signaling. Blood 2017; 130 (14) 1607-1619
    CrossrefPubMedGoogle Scholar
  • 21 Shin EK, Park H, Noh JY, Lim KM, Chung JH. Platelet shape changes and cytoskeleton dynamics as novel therapeutic targets for anti-thrombotic drugs. Biomol Ther (Seoul) 2017; 25 (03) 223-230
    CrossrefPubMedGoogle Scholar
  • 22 Bye AP, Unsworth AJ, Gibbins JM. Platelet signaling: a complex interplay between inhibitory and activatory networks. J Thromb Haemost 2016; 14 (05) 918-930
    CrossrefPubMedGoogle Scholar
  • 23 Ni H, Freedman J. Platelets in hemostasis and thrombosis: role of integrins and their ligands. Transfus Apheresis Sci 2003; 28 (03) 257-264
    CrossrefPubMedGoogle Scholar
  • 24 Moraes LA, Spyridon M, Kaiser WJ. et al. Non-genomic effects of PPARgamma ligands: inhibition of GPVI-stimulated platelet activation. J Thromb Haemost 2010; 8 (03) 577-587
    CrossrefPubMedGoogle Scholar
  • 25 Vaiyapuri S, Jones CI, Sasikumar P. et al. Gap junctions and connexin hemichannels underpin hemostasis and thrombosis. Circulation 2012; 125 (20) 2479-2491
    CrossrefPubMedGoogle Scholar
  • 26 Wei H, Davies JE, Harper MT. 2-Aminoethoxydiphenylborate (2-APB) inhibits release of phosphatidylserine-exposing extracellular vesicles from platelets. Cell Death Discov 2020; 6: 10
    CrossrefPubMedGoogle Scholar
  • 27 Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260 (06) 3440-3450
    CrossrefPubMedGoogle Scholar
  • 28 Poenie M. Alteration of intracellular Fura-2 fluorescence by viscosity: a simple correction. Cell Calcium 1990; 11 (2-3): 85-91
    CrossrefPubMedGoogle Scholar
  • 29 Bye AP, Unsworth AJ, Vaiyapuri S, Stainer AR, Fry MJ, Gibbins JM. Ibrutinib inhibits platelet integrin αIIbβ3 outside-in signaling and thrombus stability but not adhesion to collagen. Arterioscler Thromb Vasc Biol 2015; 35 (11) 2326-2335
    CrossrefPubMedGoogle Scholar
  • 30 Kanaji T, Kanaji S, Montgomery RR, Patel SB, Newman PJ. Platelet hyperreactivity explains the bleeding abnormality and macrothrombocytopenia in a murine model of sitosterolemia. Blood 2013; 122 (15) 2732-2742
    CrossrefPubMedGoogle Scholar
  • 31 Pugh N, Maddox BD, Bihan D, Taylor KA, Mahaut-Smith MP, Farndale RW. Differential integrin activity mediated by platelet collagen receptor engagement under flow conditions. Thromb Haemost 2017; 117 (08) 1588-1600
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Unsworth AJ, Bye AP, Sage T. et al. Antiplatelet properties of Pim kinase inhibition are mediated through disruption of thromboxane A2 receptor signaling. Haematologica 2021; 106 (07) 1968-1978
    CrossrefPubMedGoogle Scholar
  • 33 Bye AP, Unsworth AJ, Desborough MJ. et al. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib. Blood Adv 2017; 1 (26) 2610-2623
    CrossrefPubMedGoogle Scholar
  • 34 Pugh N, Bihan D, Perry DJ, Farndale RW. Dynamic analysis of platelet deposition to resolve platelet adhesion receptor activity in whole blood at arterial shear rate. Platelets 2015; 26 (03) 216-219
    CrossrefPubMedGoogle Scholar
  • 35 Khan AO, Slater A, Maclachlan A. et al. Post-translational polymodification of β1-tubulin regulates motor protein localisation in platelet production and function. Haematologica 2022; 107 (01) 243-259
    CrossrefPubMedGoogle Scholar
  • 36 Wersäll A, Williams CM, Brown E, Iannitti T, Williams N, Poole AW. Mouse platelet Ral GTPases control P-selectin surface expression, regulating platelet-leukocyte interaction. Arterioscler Thromb Vasc Biol 2018; 38 (04) 787-800
    CrossrefPubMedGoogle Scholar
  • 37 Flaumenhaft R, Dilks JR, Rozenvayn N, Monahan-Earley RA, Feng D, Dvorak AM. The actin cytoskeleton differentially regulates platelet alpha-granule and dense-granule secretion. Blood 2005; 105 (10) 3879-3887
    CrossrefPubMedGoogle Scholar
  • 38 Woronowicz K, Dilks JR, Rozenvayn N. et al. The platelet actin cytoskeleton associates with SNAREs and participates in alpha-granule secretion. Biochemistry 2010; 49 (21) 4533-4542
    CrossrefPubMedGoogle Scholar
  • 39 Duncan MD, Duncan KL. Cucurbitacin E targets proliferating endothelia. J Surg Res 1997; 69 (01) 55-60
    CrossrefPubMedGoogle Scholar
  • 40 Bury L, Falcinelli E, Chiasserini D, Springer TA, Italiano Jr JE, Gresele P. Cytoskeletal perturbation leads to platelet dysfunction and thrombocytopenia in variant forms of Glanzmann thrombasthenia. Haematologica 2016; 101 (01) 46-56
    CrossrefPubMedGoogle Scholar
  • 41 Cauwenberghs S, Feijge MA, Harper AG, Sage SO, Curvers J, Heemskerk JW. Shedding of procoagulant microparticles from unstimulated platelets by integrin-mediated destabilization of actin cytoskeleton. FEBS Lett 2006; 580 (22) 5313-5320
    CrossrefPubMedGoogle Scholar
  • 42 Sari-Hassoun M, Clement MJ, Hamdi I. et al. Cucurbitacin I elicits the formation of actin/phospho-myosin II co-aggregates by stimulation of the RhoA/ROCK pathway and inhibition of LIM-kinase. Biochem Pharmacol 2016; 102: 45-63
    CrossrefPubMedGoogle Scholar
  • 43 Pandey D, Goyal P, Bamburg JR, Siess W. Regulation of LIM-kinase 1 and cofilin in thrombin-stimulated platelets. Blood 2006; 107 (02) 575-583
    CrossrefPubMedGoogle Scholar
  • 44 Millard M, Odde S, Neamati N. Integrin targeted therapeutics. Theranostics 2011; 1: 154-188
    CrossrefPubMedGoogle Scholar
  • 45 Chew DP, Bhatt DL, Topol EJ. Oral glycoprotein IIb/IIIa inhibitors: why don't they work?. Am J Cardiovasc Drugs 2001; 1 (06) 421-428
    CrossrefPubMedGoogle Scholar
  • 46 Cox D. Oral GPIIb/IIIa antagonists: what went wrong?. Curr Pharm Des 2004; 10 (14) 1587-1596
    CrossrefPubMedGoogle Scholar
  • 47 Bennett JS, Zigmond S, Vilaire G, Cunningham ME, Bednar B. The platelet cytoskeleton regulates the affinity of the integrin alpha(IIb)beta(3) for fibrinogen. J Biol Chem 1999; 274 (36) 25301-25307
    CrossrefPubMedGoogle Scholar
  • 48 Aburima A, Walladbegi K, Wake JD, Naseem KM. cGMP signaling inhibits platelet shape change through regulation of the RhoA-Rho Kinase-MLC phosphatase signaling pathway. J Thromb Haemost 2017; 15 (08) 1668-1678
    CrossrefPubMedGoogle Scholar
  • 49 Falet H, Chang G, Brohard-Bohn B, Rendu F, Hartwig JH. Integrin alpha(IIb)beta3 signals lead cofilin to accelerate platelet actin dynamics. Am J Physiol Cell Physiol 2005; 289 (04) C819-C825
    CrossrefPubMedGoogle Scholar
  • 50 Zhang M, Bian ZG, Zhang Y. et al. Cucurbitacin B inhibits proliferation and induces apoptosis via STAT3 pathway inhibition in A549 lung cancer cells. Mol Med Rep 2014; 10 (06) 2905-2911
    CrossrefPubMedGoogle Scholar
  • 51 Beutler JA. Natural products as a foundation for drug discovery. Curr Protocols Pharmacol 2019; 86 (01) e67
    CrossrefPubMedGoogle Scholar
  • 52 Guo Z. The modification of natural products for medical use. Acta Pharm Sin B 2017; 7 (02) 119-136
    CrossrefPubMedGoogle Scholar
  • 53 Gehringer M, Laufer SA. Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology. J Med Chem 2019; 62 (12) 5673-5724
    CrossrefPubMedGoogle Scholar
  • 54 Kumar A, Zhang KYJ. Advances in the development of shape similarity methods and their application in drug discovery. Front Chem 2018; 6: 315
    CrossrefPubMedGoogle Scholar
  • 55 Guvench O. Computational functional group mapping for drug discovery. Drug Discov Today 2016; 21 (12) 1928-1931
    CrossrefPubMedGoogle Scholar